Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults

Lee, So‐Young; Kim, Han Wool; Lee, Ji Hyen; Kim, Kyung Hyo

doi:10.1016/j.vaccine.2015.08.002

Cited by 10 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rates of which were 92.0%, 83.0%, 89.0%, 81%, 84% for serotypes 1, 6B, 14, 19F, and 23F, respectively Jong Gyun Ahn et al. 94 Korea 2015 PPSV23 (Merck) Pneumococcal vaccine-naïve participants ≥ 65 years of age Single dose of PPV23 GMTs to all tested serotypes significantly increased after vaccination in both groups (65–74 years and ≥75 years of age) Masanari Shiramoto et al. 23 Japan 2015 PPSV23 (Merck) PPSV23-naïve healthy adults ≥65 years Single dose of PPV23 OPA GMTs 1 month after vaccination increased significantly with geometric mean fold rise ranging from 8.2 to 65.4 in the PPSV23 group Yujia Kong et al.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

Wang

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people ≥ 2 years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults.

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

Wang

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“… 59 – 61 Many other alterations, which affect both the innate and adaptive immune systems, have been described, which cannot be addressed in detail in this review. 62 – 66 All these lead to a decline of the ability to generate an adequate immune response and thus increasing the susceptibility to bacterial infections, including pneumonia. 67 …”

Section: Pneumococcal Vaccination In the Elderlymentioning

confidence: 99%

Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly

Rijkers

Yousif

Spoorenberg

et al. 2018

RMHP

View full text Add to dashboard Cite

Pneumococcal pneumonia is a serious disease with considerable morbidity and mortality in the elderly. Despite adequate antibiotic treatment, the long-term mortality of pneumococcal pneumonia remains high. Preventive measures in the form of vaccination, therefore, are warranted. Twenty-three-valent polysaccharide vaccines have a broad coverage but limited efficacy. Pneumococcal conjugate vaccines have been shown in children to be able to prevent invasive and mucosal pneumococcal diseases. It should be realized that the serotype composition of current pneumococcal conjugate vaccines is not tailored for the elderly, and that replacement disease can occur. Yet, the current 13-valent conjugate vaccine has been shown to protect against infections with vaccine serotypes. Long-term mortality of pneumococcal pneumonia should be included in policy making about the introduction of these vaccines for the elderly.

show abstract

Pneumococcal Polysaccharide Vaccines

Grabenstein¹,

Musher²

2018

Plotkin's Vaccines

View full text Add to dashboard Cite

Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults

Cited by 10 publications

References 30 publications

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly

Pneumococcal Polysaccharide Vaccines

Contact Info

Product

Resources

About